APP and Alzheimer disease: Thus, verubecestat, an inhibitor of BACE1, substantially suppressed the production of Aβ in the AβPP proteolytic pathway and cleared extracellular Aβ, resulting in 80% drop of levels of Aβ in CSF of AD patients [27,28].